momenta pharmaceuticals inc (MNTA) Key Developments
Momenta Pharmaceuticals Announces Executive Changes
Jun 25 15
Momenta Pharmaceuticals Inc. announced that Rick Shea has advised the company of his intention to step down as Chief Financial Officer (CFO) once a successor is identified and appointed. Mr. Shea will remain with the company to assist with the CFO succession and serve in a newly created role of Senior Vice President, Corporate Communications and Operations for a transition period prior to his planned retirement in 2016. Momenta has initiated a CFO search. Mr. Shea joined Momenta in October 2003 as Chief Financial Officer and Senior Vice President.
Momenta Pharmaceuticals, Inc. Announces Launch of Glatopa (Glatiramer Acetate Injection)
Jun 18 15
Momenta Pharmaceuticals Inc. announced that Sandoz has initiated its U.S. launch of once daily Glatopa (glatiramer acetate injection), a generic equivalent of daily COPAXONE 20 mg, developed under a collaboration agreement between Momenta and Sandoz. Glatopa is the first AP-rated substitutable generic indicated for the treatment of patients with relapsing-forms of multiple sclerosis (RRMS), a chronic disease of the central nervous system characterized by inflammation and neurodegeneration. Under the terms of its collaboration agreement with Sandoz, Momenta will receive a $10.0 million milestone payment upon first commercial sale. Momenta is also eligible to receive up to $120 million in remaining milestone payments upon the achievement of certain U.S. commercial and sales-based milestones for the Glatopa Glatopa was determined by the FDA to be therapeutically equivalent to daily COPAXONE 20 mg, with the same active ingredients, route of administration, strength and dosage form. Glatopa's high quality U.S.-based supply chain and manufacturing process meet rigid FDA standards, and Glatopa is fully substitutable at the pharmacy level. Sandoz has also introduced a patient support service offering that includes financial support to eligible patients, personalised injection training and 24-hour access to nurses to answer non-clinical questions.
Momenta Pharmaceuticals Announces CAFC Decision to Invalidate Remanded Teva Pharmaceuticals Patent in Daily COPAXONE 20 mg Suit
Jun 18 15
Momenta Pharmaceuticals Inc. announced that the United States Court of Appeals for the Federal Circuit (CAFC) has again found that U.S. patent No. 5,800,808, related to a method of manufacturing glatiramer acetate, is invalid as indefinite.
Momenta Pharmaceuticals to Present New Data from Phase 1 Trial of Necuparanib in Patients With Pancreatic Cancer
Jun 1 15
Momenta Pharmaceuticals Inc. will present updated data from the Phase 1 trial evaluating necuparanib in combination with nab-paclitaxel (nabP; Abraxane®) and gemcitabine (GEM) in patients with advanced metastatic pancreatic cancer (ClinicalTrials.gov Identifier NCT01621243) at the 2015 ASCO Annual Meeting on June 1, 2015 from 8:00 to 11:30 am CDT (Abstract #4114). Necuparanib was administered daily in combination with 125 mg/m2 nabP and 1000 mg/m2 GEM (Days 1, 8, and 15 of each 28-day cycle). The necuparanib starting dose was 0.5 mg/kg, which was increased via a modified 3+3 design until a maximum tolerated dose (MTD) was determined. nabP was added to the treatment regimen starting with Cohort 3. Thirty-nine patients (12 patients in the first two cohorts and 27 patients in the five subsequent cohorts) received necuparanib and were included in the analyses.
Momenta Pharmaceuticals Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-13-2015 01:40 PM
May 6 15
Momenta Pharmaceuticals Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-13-2015 01:40 PM. Venue: Encore at the Wynn, 3131 S Las Vegas Blvd, Las Vegas, Nevada, United States. Speakers: Richard P. Shea, Chief Financial Officer, Senior Vice President and Treasurer.